检索结果 - Nigel H. Russell

Refine Results
  1. 1
    Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia

    Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia 由 Alan K. Burnett, Nigel H. Russell, Robert K. Hills

    出版 2016
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  2. 2
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML) 由 Richard Dillon, Nicola Potter, Sylvie D. Freeman, Nigel H. Russell

    出版 2020
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Targeting FLT3 mutations in AML: review of current knowledge and evidence

    Targeting FLT3 mutations in AML: review of current knowledge and evidence 由 Naval Daver, Richard F. Schlenk, Nigel H. Russell, Mark J. Levis

    出版 2019
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

    Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution 由 Phennapha Klangsinsirikul, G. Ian Carter, Jenny Byrne, G Hale, Nigel H. Russell

    出版 2002
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia

    Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia 由 Erica Harris, Judith Behrens, D Samson, Amin Rahemtulla, Nigel H. Russell, Jenny Byrne

    出版 2003
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  6. 6
    The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation

    The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation 由 Mohamad Mohty, Rafael F. Duarte, Sandra Croockewit, Kai Hübel, Gunnar Kvalheim, Nigel H. Russell

    出版 2011
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  7. 7
    HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants

    HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants 由 Bronwen E. Shaw, Steven G. E. Marsh, Neema P. Mayor, Nigel H. Russell, J. Alejandro Madrigal

    出版 2005
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation

    Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation 由 Nigel H. Russell, Jenny Byrne, Rowena D. Faulkner, M Gilyead, Emma Das‐Gupta, Alexandria Porcia Haynes

    出版 2005
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy

    Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy 由 Sahra Ali, Gail Jones, Dominic Culligan, Philippa J. Marsden, Nigel H. Russell, Nicholas D. Embleton, Charles Craddock

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    The genotype distribution of the XRCC1gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia

    The genotype distribution of the XRCC1gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia 由 Claire Seedhouse, Rowena D. Bainton, Michael D. Lewis, A. Lynn Harding, Nigel H. Russell, Emma Das‐Gupta

    出版 2002
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Granulocyte-Colony–Stimulating Factor Mobilizes Bone Marrow Stem Cells in Patients With Subacute Ischemic Stroke

    Granulocyte-Colony–Stimulating Factor Mobilizes Bone Marrow Stem Cells in Patients With Subacute Ischemic Stroke 由 Nikola Sprigg, Philip M. Bath, Liancheng Zhao, Mark Willmot, Laura J. Gray, Marion Walker, Martin Dennis, Nigel H. Russell

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

    Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial 由 Nigel H. Russell, Alan K. Burnett, Robert K. Hills, Sophie Betteridge, Mike Dennis, Jelena Jovanović, Richard Dillon, David Grimwade

    出版 2018
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  13. 13
    Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

    Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Part... 由 Stephen Robinson, Anthony H. Goldstone, Stephen Mackinnon, Angelo Michele Carella, Nigel H. Russell, Carmen Ruiz de Elvira, Goli Taghipour, Norbert Schmitz

    出版 2002
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

    Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission 由 Alan K. Burnett, Anthony P. Goldstone, Robert K. Hills, Donald Milligan, Archie Prentice, John Yin, Keith Wheatley, Ann Hunter, Nigel H. Russell

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

    Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial 由 Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Ann E. Hunter, Lars Kjeldsen, John Liu Yin, Brenda Gibson, Keith Wheatley, Donald Milligan

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

    No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials 由 Rosemary E. Gale, Teodora Popa, Melissa Wright, Naeem Khan, Sylvie D. Freeman, Alan K. Burnett, Nigel H. Russell, Robert K. Hills, David C. Linch

    出版 2017
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  17. 17
    Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial

    Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial 由 Alan K. Burnett, Jamie Cavenagh, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Gail Jones, Olav Wendelboe Nielsen, Asim Khwaja, Ian Thomas, Richard E. Clark

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation

    Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Bl... 由 Gordon Cook, Graeme Smith, Keiren Kirkland, Jungwha Lee, Rachel Pearce, Kirsty Thomson, Emma Morris, Kim Orchard, Simon Rule, Nigel H. Russell, Charles Craddock, David I. Marks

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

    Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial 由 Alan K. Burnett, Robert K. Hills, Donald Milligan, Lars Kjeldsen, Jonathan Kell, Nigel H. Russell, John A. Liu Yin, Ann Hunter, Anthony H. Goldstone, Keith Wheatley

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT

    Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT 由 David Burns, Sohail Rana, Elizabeth Martin, Sandeep Nagra, Janice Ward, Husam Osman, Andrew Bell, Paul Moss, Nigel H. Russell, Charles Craddock, Christopher P. Fox, Sridhar Chaganti

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: